Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05495295RecruitingPhase 1
First test of PhOx430 for advanced solid tumors
This Phase 1 trial tests a new cancer drug, PhOx430, for people with advanced (metastatic) solid tumors that have not responded to standard treatments. It aims to find a safe dose and to see whether the drug can shrink or control cancer.
MontpellierAges 18–80 - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05914545RecruitingPhase 1
Early study drug for advanced solid tumors in adults
This Phase 1 trial tests a new experimental medicine (FZ-AD004) in adults with advanced solid tumors. It aims to see how the drug behaves in the body and whether it’s safe enough to continue in patients with measurable cancer.
ShanghaiAges 18–75 - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Dothan, AlabamaAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT07021898RecruitingPhase 1
ERAS-4001 for advanced solid tumors with mutations
This trial tests a new oral drug called ERAS-4001 for people with advanced solid tumors that have a specific genetic change and are no longer helped by standard treatments. It aims to see if the drug is safe and can shrink tumors.
Nashville, TennesseeAges 18–99 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Birmingham, AlabamaAges 16 years+ - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07159126RecruitingPhase 1
Study of DS3610a for advanced solid tumors
This trial tests a new drug called DS3610a for people with advanced solid tumors that have stopped responding to other treatments. You may be able to join if you have tried standard therapies and are willing to provide a tumor sample.
ChūōkuAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT05898399RecruitingPhase 1/Phase 2
Testing ART6043 for advanced cancers with DNA repair defects
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Grand Rapids, MichiganAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Encinitas, CaliforniaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06566079RecruitingPhase 1
Study of ISM6331 for advanced mesothelioma or other solid tumors
This trial tests an experimental drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific cell pathway (Hippo) that may be involved in tumor growth.
Denver, ColoradoAges 18 years+ - NCT06587295RecruitingPhase 1
ACM-CpG injection for advanced solid tumors that responded to immunotherapy before
This trial tests a new injection, ACM-CpG, for people with advanced or metastatic solid tumors that previously responded to immunotherapy (with or without chemotherapy) but later grew again. The goal is to see if ACM-CpG can help when other treatments have stopped working.
SingaporeAges 21–99 - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Duarte, CaliforniaAges 18 years+ - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.